Mylan Prilosec Litigation Ongoing; Omeprazole Sales Up In Fourth Quarter
This article was originally published in The Tan Sheet
Mylan Labs continues to pursue litigation against Procter & Gamble over the marketing of Prilosec OTC as the company attempts to shield its growing Rx omeprazole business from OTC competition
You may also be interested in...
The lack of bioequivalence between Prilosec OTC (omeprazole) and Rx Prilosec is irrelevant to the product's OTC status because FDA approved the OTC version's toxicological profile as part of its review, Procter & Gamble maintains
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC